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Summary
 
Chemokines are essential mediators of normal leukocyte trafficking as well as of leukocyte re-
cruitment during inflammation. We describe here a novel non-ELR CXC chemokine identi-
fied through sequence analysis of cDNAs derived from cytokine-activated primary human as-
trocytes. This novel chemokine, referred to as I-TAC (interferon-inducible T cell alpha
chemoattractant), is regulated by interferon (IFN) and has potent chemoattractant activity for
interleukin (IL)-2–activated T cells, but not for freshly isolated unstimulated T cells, neutro-
phils, or monocytes. I-TAC interacts selectively with CXCR3, which is the receptor for two
other IFN-inducible chemokines, the IFN-
 
g
 
–inducible 10-kD protein (IP-10) and IFN-
 
g
 
–
induced human monokine (HuMig), but with a significantly higher affinity. In addition, higher
potency and efficacy of I-TAC over IP-10 and HuMig is demonstrated by transient mobiliza-
tion of intracellular calcium as well as chemotactic migration in both activated T cells and
transfected cell lines expressing CXCR3. Stimulation of astrocytes with IFN-
 
g
 
 and IL-1 to-
gether results in an 
 
z
 
400,000-fold increase in I-TAC mRNA expression, whereas stimulating
monocytes with either of the cytokines alone or in combination results in only a 100-fold in-
crease in the level of I-TAC transcript. Moderate expression is also observed in pancreas, lung,
thymus, and spleen. The high level of expression in IFN- and IL-1–stimulated astrocytes sug-
gests that I-TAC could be a major chemoattractant for effector T cells involved in the patho-
physiology of neuroinflammatory disorders, although I-TAC may also play a role in the migra-
tion of activated T cells during IFN-dominated immune responses.
Key words: neuroinﬂammation • astrocytes • calcium • signaling • brain
 
C
 
hemokines are a superfamily of cytokines important in
inflammatory and immune responses due primarily to
their chemotactic activities towards subsets of leukocytes
(1–4). The superfamily is divided into four groups, CXC, CC,
C, and CX
 
3
 
C, based on the number and arrangement of con-
served cysteine motifs. The CXC, CC, and CX
 
3
 
C chemo-
kines are distinguished by the presence of one, none, or three
amino acids, respectively, between the first two cysteines. The
CXC chemokines are primarily active on neutrophils, whereas
the CC chemokines are active on monocytes and other leu-
kocytes, including lymphocytes, eosinophils, and basophils.
Fractalkine and its murine homolog, neurotactin, are the only
known CX
 
3
 
C chemokines, and, unlike other chemokines,
are displayed on the cell surface by means of a mucin-like
stalk that connects the functional NH
 
2
 
-terminal domain
with the COOH-terminal membrane-spanning domain (5,
6). The C chemokine group, distinguished by the absence
of the second and fourth cysteines, has only one known
member, lymphotactin (7–9). Both fractalkine and lym-
photactin show predominant activity toward T cells.
The CXC subfamily is subdivided into ELR
 
1
 
 and non-
ELR CXC chemokines based on the presence or absence
 
1
 
Abbreviations used in this paper:
 
 EAE, experimental autoimmune encepha-
lomyelitis; ELR, Glu-Leu-Arg; HEK, human embryonic kidney; HuMig,
IFN-
 
g
 
–induced human monokine; IP-10, IFN-
 
g
 
–inducible 10-kD pro-
tein; I-TAC, IFN-inducible T cell alpha chemoattractant; MCP, mono-
cyte chemotactic protein; SDF, stromal cell–derived factor.
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of this Glu-Leu-Arg tripeptide sequence adjacent to the
CXC motif. ELR-containing CXC chemokines include
IL-8; NAP (neutrophil-activating protein)-2; ENA (epithe-
lial-derived neutrophil-activating protein)-78; and GRO
(growth-related protein)-
 
a
 
, -
 
b
 
, and -
 
g
 
. The ELR motif is
essential for biological activity in that a mutation in any of
these amino acids dramatically affects receptor binding and
induction of leukocyte migration (10–12). The non-ELR
CXC chemokines include the IFN-
 
g
 
–inducible 10-kD pro-
tein (IP-10), the IFN-
 
g
 
–induced human monokine (Hu-
Mig), and stromal cell–derived factor (SDF)-1. IP-10 and
HuMig have a unique selectivity for T cells that have been
activated by IL-2, whereas SDF-1 has a broader range of ac-
tivities on resting and activated memory T cells, monocytes,
and granulocytes (13–16). IP-10 has been shown to be ex-
pressed in delayed-type hypersensitivity reactions in the
skin, psoriatic plaques, tuberculoid leprosy, and certain tu-
mors (17–19). Due to these observations, it has been sug-
gested that local high concentrations of IFN upregulate IP-
10 and HuMig, which then results in the recruitment of
activated/effector T cells, thereby initiating the effector
arm of T cell immunity (20).
Chemokines exert their biological activities through G
protein–coupled receptors on the surface of target cells. In
humans, four CXC chemokine receptors (CXCR1–4) and
eight CC chemokine receptors (CCR1–8) have been iden-
tified (21–32). The CXC chemokine receptors have been
shown to have the following ligand specificities: CXCR1
binds IL-8 (33); CXCR2 binds IL-8 and other ELR-contain-
ing CXC chemokines (34); CXCR3 binds IP-10 and Hu-
Mig (15); and CXCR4 binds SDF-1
 
a
 
 (35, 36). CXCR3 is
selectively expressed in activated T cells and not in other
leukocyte subpopulations. This underscores the importance
of the selective recruitment of activated T cells by IP-10
and HuMig during inflammation (15, 20).
Localized upregulation of chemokines by proinflamma-
tory cytokines like TNF, IL-1, and IFN, and the subse-
quent infiltration of leukocytes, is extremely important in
the development of both acute and chronic inflammatory
responses including immediate- and delayed-type hypersen-
sitivity responses. Chemokine expression has been detected
in the T cell–mediated disease experimental autoimmune
encephalomyelitis (EAE), an animal model for multiple
sclerosis. Expression of IP-10 and two CC chemokines, MCP
(monocyte chemoattractant protein)-1 and RANTES (reg-
ulated on activation, normal T cell expressed and secreted),
coincides with the onset of clinical EAE (37–39). Presum-
ably, autoreactive T cells enter the central nervous system
and secrete proinflammatory cytokines that cause local pro-
duction of chemokines. These chemokines promote fur-
ther infiltration of inflammatory cells, resulting in lesion
formation and demyelination indicative of multiple sclero-
sis (40). The astrocyte has been identified as an important
source of chemokine expression in EAE (37). Furthermore,
astrocytoma cells stimulated with TNF produce IL-8,
MCP-1, and IP-10 (41). To identify additional genes that
might contribute to neuroinflammatory disease pathology,
we sequenced cDNAs derived from proinflammatory cyto-
kine-stimulated primary human astrocytes and performed
bioinformatic analysis. In this study, we report a novel
non-ELR CXC chemokine identified through this ap-
proach, and describe its expression, biological activity, and
receptor usage.
 
Materials and Methods
 
Reagents.
 
The recombinant chemokines IP-10 and HuMig
were obtained from PeproTech, Inc. (Rocky Hill, NJ). Restric-
tion enzymes and molecular biology reagents were from New
England Biolabs (Beverly, MA), GIBCO BRL (Gaithersburg,
MD), or Boehringer Mannheim (Indianapolis, IN). BSA and hu-
man collagen type IV were obtained from GIBCO BRL. RPMI
1640 medium was from BioWhittaker (Walkersville, MD). RNAs
used in reverse transcriptase PCR analysis were either purchased
(Clontech, Palo Alto, CA) or generated using Trizol reagent
(GIBCO BRL) as specified by the manufacturer. Human primary
monocytes were isolated and cultured as described previously
(22); human microglial cell line SV-A3 (GFAP
 
2
 
; CD68
 
1
 
) was
derived by immortalizing primary human microglia with aden-
ovirus E1b and SV40 large T antigens. Eosinophils were isolated
by negative selection using magnetic beads. Neutrophils were
isolated as described previously (42).
 
Identification of I-TAC cDNA Sequence.
 
A cDNA library was
constructed at Incyte Pharmaceuticals, Inc. (Palo Alto, CA) from
polyA
 
1
 
 RNA isolated from human fetal astrocytes cultured in
DMEM plus 10% FCS for up to 1 mo. A second cDNA library
was constructed from polyA
 
1
 
 RNA isolated from similar cells
that had been stimulated with TNF-
 
a
 
, IFN-
 
g
 
, and IL-1
 
b
 
 (each at
200 U/ml) for 12 h. Library synthesis was initiated using a 3
 
9
 
oligo dT primer that contained a NotI site, followed by second
strand synthesis, blunting with T4 DNA polymerase, ligation to
SalI adapters, and digestion with SalI and NotI. cDNAs were
then ligated directionally into pSPORT1 (GIBCO BRL) using
SalI (5
 
9
 
) and NotI (3
 
9
 
). Single pass sequence information from the
5
 
9
 
 end of random cDNA clones was generated at Incyte by auto-
mated DNA sequencing. Novel sequences were further analyzed
using the Basic Local Alignment Search Tool (BLAST, National
Center for Biotechnology Information, Bethesda, MD; reference
43) to define similarities to known genes or gene families.
 
Cloning of Full-length I-TAC cDNA.
 
Sequence information from
the expressed sequence tag cluster NCY580854 (which contained
the 5
 
9
 
 end of a novel chemokine) was used to design the follow-
ing internal primers for 3
 
9
 
 RACE: 5
 
9
 
-GTGTGCTACAGTTGT-
TCAAGGC-3
 
9
 
 and 5
 
9
 
-GGACGCTGTCTTTGCATAGGC-3
 
9
 
. 3
 
9
 
RACE products were generated using the 3
 
9 
 
RACE System for
Rapid Amplification of cDNA Ends (GIBCO BRL) according to
manufacturer’s instructions with stimulated astrocyte RNA as
template. Amplification products were gel purified and subcloned
into pCR2.1 (Invitrogen, Carlsbad, CA) for automated sequence
analysis using an Applied Biosystems Sequencer (model 373; Ap-
plied Biosystems, Inc., Foster City, CA). Sequence data obtained
from these clones was assembled with the original NCY580854
cluster sequences to generate an 
 
z
 
1,400 bp consensus sequence
for I-TAC. The entire coding sequence was then PCR amplified
using the following primers, designed to incorporate a Kozak se-
quence and restriction sites convenient for subcloning into
pcDNA3 (Invitrogen): 5
 
9
 
 primer: 5
 
9
 
-CGGGATCCGCCGAC-
CATGAGTGTGAAGGGCATGGCTATAGC-3
 
9
 
; 3
 
9
 
 primer:
5
 
9
 
-CCGCTCGAGCGGTCATTAAAAATTCTTTCTTTCA-
ACTTTTTTGATTATAAGCC-3
 
9
 
. The PCR product was gel 
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isolated, digested with BamHI and XhoI, ligated to pcDNA3,
and used to transform 
 
Escherichia coli
 
 DH5
 
a
 
 cells. Correct clones
were identified by restriction analysis and the sequence was con-
firmed by automated sequence analysis as above.
 
Northern Analysis.
 
Human Multiple Tissue Northern Blots were
purchased from Clontech and hybridized with a 224-bp fragment
of I-TAC coding sequence labeled by random priming (Prime-It
II; Stratagene, La Jolla, CA) in the presence of [
 
32
 
P]dCTP. Hy-
bridization was carried out in Express-Hyb Solution (Clontech)
under stringent conditions as specified by the manufacturer.
 
Reverse Transcriptase PCR Analysis of I-TAC Expression.
 
First
strand cDNA was generated from total RNA via oligo dT primed
reverse transcription. Real time quantitative PCR was performed us-
ing a sequence detection system (ABI Prism 7700; Perkin-Elmer
Corp., Norwalk, CT) using TaqMan Fluorogenic oligonucleotide
probes (Perkin-Elmer Corp.). Relative I-TAC levels were calculated
by normalizing to 
 
b
 
-actin. Probe and primer sequences are as fol-
lows: 
 
b
 
-actin forward, AGATCATTGCTCCTCCTGAGC; 
 
b
 
-actin
reverse, ACGCAACTAAGTCATAGTCCGC; 
 
b
 
-actin probe,
(6FAM)AGCAGATGTGGATCAGCAAGCAGGA(TAMRA);
I-TAC forward, GCTATAGCCTTGGCTGTGATAT; I-TAC
reverse, CAGGGCCTATGCAAAGACA; and I-TAC probe,
(6FAM)TGTGTGCTACAGTTGTTCAAGGCTTCCC(TA-
MRA). All reactions were carried out using the TaqMan PCR
reagent kit with final reagent concentrations at 10% glycerol, 5.0
mM MgCl
 
2
 
, 200 
 
m
 
M each of dATP, dCTP, and dGTP, 400 
 
m
 
M
dUTP, and 1
 
3
 
 TaqMan Buffer A. Primer concentrations were
50 nM and probe concentrations were 200 nM. 1.0 
 
m
 
l template
cDNA was used for each reaction along with 1.25 U Amplitaq
Gold and 0.5 U AmpErase Uracil 
 
N
 
-Glycosylase (both from Per-
kin-Elmer Corp.). Cycling conditions were 2 min at 50
 
8
 
C, 10
min at 94
 
8
 
C, followed by 40 cycles of 15 s at 94
 
8
 
C and 90 s at
60
 
8
 
C. Three replicate reactions were set up for each sample for
both 
 
b
 
-actin and I-TAC. Relative quantities were calculated by
first subtracting the average threshold cycle (Ct) for I-TAC from
the 
 
b
 
-actin average Ct to generate normalized I-TAC Ct values
and then adding the lowest normalized Ct value to each to gener-
ate the value for 
 
n
 
. Then take 2
 
n
 
 to generate a relative quantity
for each with the lowest level sample 
 
5 
 
1.00.
 
Chromosomal Localization.
 
A panel of human/rodent somatic
cell-hybrid genomic DNAs (BIOS Laboratories, New Haven,
CT) was amplified by PCR using I-TAC–specific primers (for-
ward, 5
 
9
 
-CCTTGGCTGTGATATTGTGTGC-3
 
9
 
 and reverse,
5
 
9
 
-CTGCCACTTTCACTGCTTTTACC-3
 
9
 
). PCR conditions
were 30 cycles of denaturation at 94
 
8
 
C for 45 s, annealing at 58
 
8
 
C
for 30 s, and extension at 68
 
8
 
C for 5 min using the Robocycler
(Stratagene). PCR products were analyzed by agarose gel electro-
phoresis and discordance analysis was performed as specified by
the manufacturer.
 
Chemical Synthesis of I-TAC.
 
The predicted mature I-TAC
amino acid sequence was synthesized using automated Fmoc-
based solid phase peptide chemistry on a Solid Phase Peptide Syn-
thesizer (model 431A) using software version Synthassist 2.0
(both from Applied Biosystems, Inc.) retrofitted with deprotec-
tion monitoring. HBTU (benzotriazole-yl tetramethyluronium
hexafluorophosphate) activation and single amino acid coupling
cycles were used, except after sluggish deprotection steps, in
which case the following residue was double coupled. Syntheses
were started using 0.25 mmol preloaded Fmoc Lys (Boc) resin
(Applied Biosystems, Inc.), 50% of the resin cake was removed
midway through the synthesis, and the synthesis was completed.
The final synthesis resin was cleaved and deprotected by treat-
ment with a solution of 83% TFA (trifluoroacetic acid), 5% phe-
nol, 5% water, and 2.5% ethandithiol for 1 h at 23
 
8
 
C. The mix-
ture was filtered, the TFA filtrate was diluted into 50 ml of
diethylether, and the precipitated crude peptide salt was collected
by centrifugation. The peptide was purified by preparative re-
verse-phase HPLC (20 
 
3 
 
250 mm C18 column; Waters, Milford,
MA) using a water/acetonitrile (0.1% TFA) gradient. Fractions
were assayed by analytical HPLC (4.5 
 
3 
 
250 mm C18 column;
Vydac, Hesparia, CA). Appropriate fractions were pooled (
 
.
 
85%
purity) and the resulting solution was adjusted with folding buffer
additives (final concentrations: 0.5 mM cysteine, 0.5 mM cystine,
10 mM methionine, 75 mM Hepes, pH 8.0, 0.05–0.5 mg/ml
peptide). The folding reaction was essentially complete after 15 h
at 4
 
8
 
C as indicated by shift to shorter retention time on analytical
HPLC. The oxidized product was purified as above to 
 
.
 
98% pu-
rity. Concentration was estimated by UV absorbance at 280 nm
and confirmed by amino acid analysis (University of Michigan
Protein Structure Facility, Ann Arbor, MI). The product was ali-
quoted, lyophilized, and stored at 
 
2
 
80
 
8
 
C. Electrospray (Sciex
API100; Perkin-Elmer, Applied Biosystems Division, Foster
City, CA) mass of reduced chemokine: 8046.6 daltons (calcu-
lated: 8045.8 daltons); mass of folded chemokine: 8042.6 daltons
(calculated: 8041.8 daltons).
 
Isolation and Culture of Human T Lymphocytes.
 
PBMCs were iso-
lated from heparinized human blood using Accuspin tubes (Sigma
Chemical Co., St. Louis, MO). Two different cell culture proce-
dures were used. In the first method, blast cells were prepared by
washing the mononuclear cells in RPMI medium, culturing for 3 d
in RPMI medium with PHA (2 
 
m
 
g/ml; Murex, Dartford, En-
gland), and propagating in 50 U/ml IL-2 (Collaborative Biomed-
ical Products, Bedford, MA). Cells were used 9–21 d after addition
of IL-2. In the second cell preparation method, T cells were first
separated from the mononuclear fraction using T cell purification
columns (R&D Systems, Minneapolis, MN) and then cultured in
human IL-2 (400 U/ml) for 7 days in RPMI medium containing
10% FCS.
 
Generation of Stable CXCR3 Transfectants.
 
The cDNA encod-
ing CXCR3 was amplified from mRNA isolated from activated
T cells with the following primers: forward primer, 5
 
9
 
-GC-
GAATTCAAGCACCAAAGCAGAGGGG-3
 
9
 
 and reverse primer,
5
 
9
 
-GCTCTAGATGGGCGAAAGGGGAGCCCG-3
 
9
 
. The PCR
product obtained was gel purified, digested with EcoRI and
XbaI, and cloned into the EcoRI and XbaI sites of pcDNA3 (In-
vitrogen). The sequence was verified by automated sequence
analysis as above. Human embryonic kidney (HEK)293 cells were
transfected with the CXCR3 expression construct using lipo-
fectamine as specified by the manufacturer (GIBCO BRL), and
selection for G418 resistance (1 mg/ml, wt/vol) was initiated 24 h
after transfection. After 
 
z
 
2 wk, G418-positive colonies were
picked and further cloned to obtain clonal cell lines. Clonal cell
lines were screened by their ability to mobilize intracellular cal-
cium in response to IP-10. CXCR3 stable transfectants in a
mouse pre-B cell line, 300-19, and in Jurkat cells have been de-
scribed previously (15).
 
Calcium Mobilization Assay.
 
T cell blasts and CXCR3 trans-
fectants described above were harvested in flux buffer (13 Hanks,
10 mM Hepes, 1.6mM CaCl2, pH 7.3), loaded with INDO-1-AM
(20mg/ml) for 30 min at 378C, and washed in flux buffer. Cells
(0.25 3 106/ml flux buffer) were placed in a continuously stirred
cuvette at 378C in a Photon Technology Inc. (South Brunswick,
NJ) fluorimager. Cells were stimulated with various chemokines
and the calcium-related fluorescence changes were recorded. The
intracellular concentration of Ca21 was determined as described
previously (22).2012 I-TAC, a Novel Non–Glu-Leu-Arg (ELR) CXC Chemokine
In Vitro Chemotaxis Assay. Lymphocyte and PHA blast
chemotaxis to various chemokines was measured using a 48-well
Boyden’s chamber (Neuro Probe, Inc., Cabin John, MD). In
brief, agonists were diluted in RPMI medium containing 0.1%
BSA and added to the bottom wells of a 48-well chemotaxis
chamber. Cells were resuspended in RPMI/BSA and 105 cells
were added to the top wells of the chamber. A 5-mm PVP-free
filter coated on the bottom with 10 mg/ml of human type IV col-
lagen was used. Chambers were incubated for 60 min in a 5%
CO2-humidified incubator at 378C. After the incubation period,
the filters were stained with Dif-Quik and the number of PBMCs
migrating to the lower surface was counted in six randomly cho-
sen high powered fields.
I-TAC Binding to CXCR3 Transfectants. I-TAC was 125I-iodi-
nated using the Bolton and Hunter procedure as described previ-
ously (44). Binding assays were performed in triplicate in 200-ml
volumes of binding buffer (50 mM Hepes, pH 7.4, 0.5% BSA,
1 mM CaCl2, and 5 mM MgCl2) in the presence of 0.27 nM of
radiolabeled I-TAC and various concentrations of unlabeled
chemokines at 48C for 60 min. I-TAC bound to cells was sepa-
rated from unbound by first diluting the samples in 10 vol of 10 mM
Hepes, pH 7.4, and 0.5 M NaCl and then filtering on GF/C fil-
ters (presoaked 20 min in 0.3% polyethylenimine) using a vac-
uum aspirator. Filters were then washed twice with the same
buffer, air-dried and counted on a Beckman gamma counter.
Scatchard analysis was performed as described previously (22).
Results
Identification of I-TAC. Through a collaboration with
Incyte Pharmaceuticals, Inc., a cDNA library was con-
structed from RNA isolated from primary human astro-
cytes stimulated for 12 h with IFN-g, IL-1b, and TNF-a
(200 U/ml each). Approximately 4,000 sequences were
generated at Incyte and screened to identify known and
novel sequences using the program BLAST (43). The se-
quence of a novel clone, NCY580854, was most closely
related to the non-ELR CXC chemokine, IP-10. This se-
quence was representative of a cluster of clones present at
0.35% in this stimulated astrocyte library. Full-length se-
quence of the cDNA corresponding to clone NCY580854
was obtained by 39-RACE as described in Materials and
Methods. The consensus sequence of various overlapping
cDNAs corresponding to clone NCY580854 is shown in
Fig. 1. The sequence contains an open reading frame of 94
amino acids with a 39 untranslated region of z1,000 bp.
(Fig. 1). A rare polyadenylation signal (AATACA; refer-
ence 45) is present 10 bases upstream of the polyA1 track
(Fig. 1). Part of the sequence of clone NCY580854 is iden-
tical to the recently described b-R1 cDNA fragment (46),
except that the published b-R1 sequence has an insertion
of six bases (TCGAGC) at position 302, a single base dele-
tion at positions 275, 277, and 283, a C®T change at posi-
tion 335, a G®A change at position 353, and an A®T
change at position 410 (Fig. 1). A re-examination of the b-R1
sequence data revealed that the deletions and insertions are
not present in that cDNA and the base differences are most
likely sequence polymorphisms (Ransohoff, R., personal
communication). Therefore, we conclude that NCY580854
and b-R1 are encoded by the same gene. Due to its IFN
inducibility and biological activity (see below), we have
named this novel chemokine I-TAC (IFN-inducible T cell
a chemoattractant). Based on the hydrophobicity profile of
the coding sequence of NCY580854 and sequence com-
parisons with IP-10 and HuMig, we propose that signal
peptide cleavage occurs between Gly21 and Phe22 (Fig. 1).
The predicted mature polypeptide is 72 amino acids in
length, contains 4 conserved cysteines typical of chemo-
kines, and does not contain an ELR motif. Like other
chemokines, it is highly basic with an isoelectric point of
10.79. I-TAC has greater similarity (z40%) to the non-
ELR CXC chemokines, IP-10 and HuMig, than to any
Figure 1. Nucleotide sequence
and predicted amino acid sequence
of human I-TAC. The deduced
amino acid sequence is indicated
in single letter codes below the
cDNA sequence, with the stop
codon indicated by an asterisk.
The putative signal peptide is
underlined. The polyadenylation
signal is of a rare type and is
marked with a double underline.
The sequence is available from
EMBL/GenBank/DDBJ under
accession number AF030514. 
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other known chemokines. The alignment and phylogenetic
relationship of I-TAC to other CXC chemokines is shown
in Fig. 2, 
 
A
 
 and 
 
B
 
.
 
Chromosomal Localization of I-TAC.
 
The chromosome lo-
cation of I-TAC was determined by PCR amplification of
human/rodent somatic cell-hybrid genomic DNAs with
primers designed to flank the predicted position of intron 1
(based on alignment of I-TAC cDNA with the known
gene structure of IL-8; reference 47). These primers ampli-
fied a genomic product of 
 
z
 
700 bp, whereas the cDNA
product is 105 bp (data not shown). No product was de-
tected in either hamster or mouse genomic DNA controls.
The PCR analysis of the somatic cell-hybrid genomic
DNA panel using these primers yielded products only in
hybrids containing human chromosome 4 (data not shown).
Thus, the gene encoding I-TAC maps to chromosome 4 as
do other CXC chemokines, with the exception of SDF-1.
 
Expression of I-TAC mRNA.
 
To determine the tissue
distribution of I-TAC mRNA, we performed Northern
blot hybridization using the I-TAC cDNA as probe. The
highest levels of I-TAC mRNA were detected in periph-
eral blood leukocytes, pancreas, and liver, followed by thy-
mus, spleen, and lung (Fig. 3). Lower levels were detected
in placenta, prostate, and small intestine. The size of the
I-TAC mRNA is 
 
z
 
1.4 kb, the same size as the full length
cDNA sequence in Fig. 1. However, a transcript of 
 
z
 
4.5 kb
was also detected in pancreas, peripheral blood leukocytes,
and spleen (Fig. 3). Interestingly, a heterogeneous range of
transcripts from 
 
z
 
1.3 to 6 kb was detected in liver and
small intestine, which cannot be explained by RNA degra-
dation, since discreet bands were detected in these lanes us-
ing other genes as probes (data not shown). These bands
Figure 2. Sequence alignment and phylogenetic relationship of I-TAC
with other known CXC chemokines. (A) Amino acid alignment of I-TAC
with CXC chemokines. The alignment was generated with the program
Megalign (DNA Star, Madison, WI) using the Clustal method and then
manually aligned to obtain the maximum amino acid similarity. Amino
acid residues conserved in all sequences are boxed and shaded. Unshaded
boxed regions indicate amino acid residues conserved between I-TAC
and at least two other CXC chemokines. (B) Phylogenetic tree showing
the relationships between I-TAC and known CXC chemokines. The
alignment above was used to generate a phylogenetic tree by the Meg-
align program and the extent of similarity between sequences is indicated
below the phylogenetic tree.
   
This document was created with FrameMaker 4.0.42014 I-TAC, a Novel Non–Glu-Leu-Arg (ELR) CXC Chemokine
may represent alternatively spliced I-TAC transcripts, or
cross-hybridizing mRNAs, although we have not investi-
gated this further.
To investigate the regulation of I-TAC mRNA by IFN,
we used real time quantitative reverse transcriptase PCR
(48). b-actin mRNA was simultaneously amplified and the
levels of I-TAC PCR product were normalized to the lev-
els of b-actin PCR product. The lowest level of I-TAC
PCR product detected within the samples analyzed was ar-
bitrarily set at one and corresponds to the mRNA detected
in cultured unstimulated astrocytes (Table 1). IFN-g up-
regulated I-TAC mRNA in all cell types examined. The
greatest induction, 14,000-fold, was observed in astrocytes.
Furthermore, IL-1 synergized with IFN-g to give an
z400,000 fold increase of I-TAC mRNA in astrocytes.
This synergy was not observed in monocytes. In mono-
cytes, IFN-b induction of I-TAC mRNA was similar to
IFN-g induction. Finally, IFN induction resulted in a sig-
nificantly higher I-TAC mRNA level in astrocytes com-
pared with the basal level detected in pancreas, lung, or
liver (Table 1). These results demonstrate a tremendous
upregulation of I-TAC mRNA in astrocytes stimulated
with IFN-g together with IL-1, and further confirm the
previous report that the b-R1 gene encoding I-TAC is
regulated by IFN (46).
Chemotactic Activity of I-TAC. Since I-TAC shares the
greatest sequence similarity with IP-10 and HuMig, we
predicted that it would have similar biological activities and
evoke similar responses in T cells. To test this hypothesis,
we chemically synthesized the predicted mature I-TAC
polypeptide and used the purified material to perform chemo-
taxis  assays on PHA-stimulated peripheral blood T cells
cultured in the presence of IL-2 for 8–15 d. I-TAC in-
duced a potent chemotactic response in activated T cells that
peaked at 10 nM and decreased at higher concentrations in
a typical bell-shaped chemotactic response curve (Fig. 4).
Figure 3. Northern blot analysis of the tissue distribution of I-TAC.
Multiple Tissue Northern Blot filters (Clontech), containing 2 mg
poly(A)1 mRNA/lane, were hybridized with a 32P-labeled human I-TAC
cDNA probe. Conditions for hybridization and subsequent washings
were as indicated in Materials and Methods. Autoradiography was per-
formed at 2708C with intensifying screen for 24–72 h. Migration of mo-
lecular weight markers in kilobases are shown between the blots.
Table 1. Real Time Quantitative Reverse Transcriptase PCR of 
I-TAC mRNA
Cell type (6 stimulation) Relative level of I-TAC mRNA*
Astrocytes 1.00
Astrocytes 1 IL-1 3,221
Astrocytes 1 IFN-g 14,164
Astrocytes 1 IL-1 and IFN-g 467,087
Monocytes 4
Monocytes 1 IL-1 5
Monocytes 1 IFN-g 399
Monocytes 1 IL-1 and IFN-g 222
Monocytes 1 IFN-b 425
SV-A3 (microglial cell line) 5
SV-A3 1 IFN-g 48,308
Pancreas 4,021
Lung 637
Liver 35
*Levels of I-TAC mRNA were calculated as described in Materials and
Methods.
Figure 4. Chemotactic response of activated T cells to I-TAC. PHA-
stimulated T cells grown in the presence of IL-2 for 10–15 d were used in
chemotaxis assays as described in Materials and Methods. Each assay was
done in triplicate and the cells migrating in response to the indicated con-
centration of chemokine were scored in five to eight high powered fields
(HPF). Error bars were determined by first calculating the average num-
ber of cells in the HPF and then determining the standard deviation
within the three different wells.2015 Cole et al.
I-TAC was equipotent to IP-10, but the efficacy was much
higher, i.e., twice as many cells migrated in response to 10
nM I-TAC than to 10 nM IP-10 (Fig. 4). No response was
observed with freshly isolated, untreated T cells, mono-
cytes, or granulocytes (data not shown), indicating that,
like IP-10 and HuMig, I-TAC is selective for activated T
cells (13).
Intracellular [Ca21] Measurements. We then determined
if I-TAC caused changes in intracellular calcium levels in
activated T cells, as is typical for chemokine-induced sig-
naling in leukocytes. I-TAC caused a rapid and transient
increase in intracellular calcium level in a dose-dependent
manner with peak activity at 10 nM (Fig. 5 A). I-TAC was
considerably more potent (EC50: z6 nM) than IP-10 and
HuMig (EC50: z20 and z30 nM, respectively). In addi-
tion, the I-TAC response was more robust: up to 800 nM
calcium was mobilized by I-TAC compared with 200 and
400 nM by HuMig and IP-10, respectively (Fig. 5 B). No
change in intracellular calcium level was detected in neu-
trophils, eosinophils, or monocytes, consistent with the
lack of chemotaxis in these cells (data not shown). These
results confirmed the activity and specificity observed in
the chemotaxis assay and in addition showed that I-TAC is
more potent and efficacious than either IP-10 or HuMig.
Cross-Desensitization Analysis. To examine receptor use
by I-TAC, we used calcium mobilization as a read-out and
performed cross-desensitization experiments using activated
T cells. Although homologous desensitization was seen with
all three chemokines (data not shown), an interesting pat-
tern of cross-desensitization was observed (Fig. 6). First,
IP-10 at 1,000 nM and HuMig at 500 nM completely
cross-desensitized each other, indicating that they interact
with one receptor, most likely CXCR3 (15). 50 nM I-TAC
desensitized the response to 1,000 nM IP-10 and 500 nM
HuMig, indicating that I-TAC most likely interacts with
the IP-10/HuMig receptor. However, neither IP-10 at
1,000 nM nor HuMig at 500 nM completely desensitized
the response to 50 nM I-TAC (Fig. 6). These results sug-
gest two possibilities. The first is that I-TAC interacts with
multiple receptors, at least one of which does not bind IP-10
or HuMig. Alternatively, it is possible that all three chemo-
Figure 5. Mobilization of intracellular calcium in activated T cells. (A)
Concentration-dependent [Ca21]i changes induced by I-TAC in IL-2–stim-
ulated T cell blasts. I-TAC was added at 50, 10, 5, and 0.5 nM to INDO-
1–loaded cells and [Ca21]i-dependent fluorescence changes were re-
corded. The data shown is from one representative experiment of at least
four separate experiments using cells from different donors. (B) Dose-
response curves of I-TAC, IP-10, and HuMig on IL-2–stimulated T cell
blasts. Chemokine was added at 0.25, 0.5, 5, 10, 50, and 500 nM to
INDO-1–loaded cells and intracellular [Ca21] changes were monitored as
above. These data are compiled from two separate experiments using cells
from different donors.
Figure 6. Cross-desensitization of IL-2–stimulated T cell blasts.
Chemokine concentrations used were 1,000 nM for IP-10, 500 nM for
HuMig, and 50 nM for I-TAC. INDO-1–loaded cells were exposed se-
quentially to the indicated chemokines. These data are from one repre-
sentative experiment of four separate experiments using cells from differ-
ent donors.2016 I-TAC, a Novel Non–Glu-Leu-Arg (ELR) CXC Chemokine
kines interact with one receptor, but I-TAC interacts with
at least one site or conformational form bound by neither
IP-10 nor HuMig.
Interaction of I-TAC with CXCR3. Cross-desensitization
experiments suggested that IP-10, HuMig, and I-TAC can
all interact with the same receptor. Since an IP-10/HuMig
receptor (CXCR3) has been identified, we tested the abil-
ity of I-TAC to interact with CXCR3. I-TAC caused a
potent chemotactic response in 300-19 transfectants stably
expressing CXCR3. The response peaked at 10 nM and
decreased at higher concentrations in a typical chemotactic
response (Fig. 7). No response to I-TAC was observed in
parental 300-19 cells. I-TAC was both more potent (maxi-
mum migration at 10 nM for I-TAC versus z100 nM for
IP-10 and HuMig) and more efficacious (twice as many
cells migrated in response to 10 nM I-TAC) than IP-10 or
HuMig (Fig. 7). To further examine the interaction with
CXCR3, the change in the level of intracellular calcium in
300-19 CXCR3 transfectants was monitored after chal-
lenge with various chemokines. I-TAC caused a dose-depen-
dent  response that peaked at 10 nM (Fig. 8), while no
change in intracellular calcium was observed in parental
300-19 cells (data not shown). In comparison to IP-10 or
HuMig, I-TAC mobilized twice as much calcium, z2,000
nM compared with z1,000 nM for IP-10 and HuMig.
The EC50 of I-TAC was z1 nM compared with z10 nM
for IP-10 and z50 nM for HuMig (Fig. 8). The results of
Ca21 cross-desensitization experiments using the 300-19
CXCR3 transfectants are shown in Fig. 9. Similar to what
was observed on T cells, a relatively low concentration of
I-TAC (50 nM) completely desensitized the response to ei-
ther 1,000 nM IP-10 or 500 nM HuMig, although IP-10
or HuMig at these elevated concentrations caused only a
partial desensitization of I-TAC responses (Fig. 9). The fail-
ure of IP-10 or HuMig to completely desensitize I-TAC re-
sponses in cloned CXCR3 transfectants is consistent with
the hypothesis that I-TAC binds multiple sites or confor-
mational forms of this receptor. Regardless, these results in-
dicate that I-TAC is a highly potent and efficacious ligand
for CXCR3.
Binding of I-TAC to CXCR3 Transfectants. To demon-
strate that I-TAC binds to CXCR3, and to measure its af-
finity compared with IP-10 and HuMig, we performed
binding assays. No I-TAC binding was observed over
background on the 300-19 transfectants, presumably due to
low receptor expression (data not shown). However, radio-
labeled I-TAC bound specifically to HEK293 transfectants
stably expressing CXCR3 (5976 6 90 cpm) and not to pa-
rental HEK293 cells (1551 6 48 cpm). The binding to the
HEK293 transfectants was displaceable with increasing
concentrations of unlabeled I-TAC (Fig. 10). Scatchard
analysis revealed two sites, a high affinity site of 0.3 nM and
a low affinity site of 36 nM (Fig. 10, n 5 3 experiments).
Figure 7. Chemotaxis of stable CXCR3 transfectants. 300-19 transfec-
tants expressing CXCR3 (clone MLRA-A5) were challenged with I-TAC
(squares), HuMig (circles), and IP-10 (diamonds). Chemotaxis was done as
previously described (15). The incubation time for chemotaxis was 2 h.
I-TAC responses to nontransfected 300-19 cells are also shown (triangles).
Figure 8. Mobilization of intracellular calcium in stable CXCR3 trans-
fectants. Concentration-dependent [Ca21]i changes induced by I-TAC,
HuMig, or IP-10 on INDO-1–loaded 300-19/CXCR3 transfectants
were determined as described above. Doses were as indicated.2017 Cole et al.
When unlabeled IP-10 or HuMig was used to displace ra-
diolabeled I-TAC, the dose-response curve shifted to the
right. The IC50 for I-TAC was z1 nm, whereas IP-10 and
HuMig IC50 values were z70 and z300 nM, respectively.
Direct binding of labeled IP-10 or HuMig to CXCR3 was
not detectable above background binding (data not shown).
Taken together, these data suggest that IP-10 and HuMig
have a low affinity for CXCR3 expressed in HEK293 cells.
Since I-TAC has a significantly higher affinity for CXCR3,
as well as higher potency and efficacy than IP-10 or Hu-
Mig, we conclude that I-TAC is the dominant ligand for
this receptor.
Discussion
We have identified a novel non-ELR CXC chemokine,
termed I-TAC, through sequencing of cDNAs derived
from stimulated astrocytes. The cDNA encoding I-TAC is
identical to b-R1, a recently described gene that is differen-
tially regulated by INF-b (46). I-TAC shares greatest se-
quence similarity with the chemokines IP-10 and HuMig
and we provide evidence that I-TAC binds to the IP-10/
HuMig receptor, CXCR3. However, I-TAC has a much
higher affinity for CXCR3 than have either IP-10 or Hu-
Mig, as demonstrated by displaceable binding. Scatchard
analysis revealed two sites for I-TAC, one high affinity and
one low affinity. No direct binding was detected on trans-
fectants or activated T cells with radiolabeled IP-10 or Hu-
Mig, possibly due to lower affinity for CXCR3. The im-
portance of these interactions in vivo is not clear. IP-10, for
example, has been shown to interact with proteoglycans, as
may also be possible for HuMig and I-TAC. The influence
of these associations on receptor binding and activation is
not yet fully understood (49).
I-TAC is more potent and efficacious than either IP-10
or HuMig in its ability to mobilize intracellular calcium and
as a chemotactic factor (rank order potency I-TAC .
HuMig < IP-10). However, calcium desensitization ex-
periments revealed an interesting phenomenon. In both ac-
tivated T cells and transfected cell lines expressing CXCR3,
I-TAC completely blocked the response to a subsequent
challenge with IP-10 or HuMig, consistent with their
binding to the same receptor. Unexpectedly, the reverse
was not true. Even a high concentration of IP-10 or Hu-
Mig could not completely desensitize I-TAC responses.
Since these results are seen with the cloned CXCR3, it ap-
pears that these three chemokines may interact differently
with the receptor. It is conceivable that the receptor may
exist in different conformations, or have multiple binding
sites, and that I-TAC interacts with conformations or sites
which cannot interact with IP-10 and HuMig. Neverthe-
less, our results show that I-TAC is the dominant ligand for
CXCR3 due to higher affinity, potency, and efficacy when
compared with IP-10 and HuMig. It is important to note
that dominant and weak ligands for CCR2 have also been
reported. MCP-1 is considerably more potent than MCP-3
in the mobilization of intracellular calcium, making it the
dominant ligand. In addition, saturating levels of MCP-3
do not completely desensitize MCP-1 responses (50).
The existence of dominant and weak ligands may have
implications for the roles of multiple chemokines at inflam-
matory sites. For example, weaker ligands captured on en-
dothelial cells may initiate firm adhesion of leukocytes,
then more dominant ligands produced at inflammatory loci
direct leukocyte recruitment. Such a “hierarchy” of chemo-
attractants has been demonstrated in vitro where different
chemotactic factors, acting via multiple receptors, “navi-
gate” leukocytes in different directions (51). Our studies would
suggest that this phenomenon could also occur by chemo-
kines acting at the same receptor.
In agreement with studies describing the regulation of
CXCR3, I-TAC has potent chemotactic activity for IL-
2–stimulated T cells and is not active on resting and naive
T cells. As such, I-TAC may not play a role in T cell traffick-
ing under normal conditions, but may have its greatest ef-
fect during immune response to foreign antigens, where
IL-2 has been generated. Antigen recognition by unstimu-
lated naive/memory T cells in secondary lymphoid organs
leads to T cell activation, IL-2 production, and clonal expan-
sion of antigen-selective T cells (52, 53). I-TAC released at
the site of initial insult may then recruit these effector T
cells. This scenario is consistent with the upregulation of
I-TAC by acute phase proteins, such as IL-1 and the IFNs,
Figure 9. Cross-desensitization of 300-19/CXCR3 transfectants. Che-
mokine concentrations used were 1,000 nM for IP-10, 500 nM for HuMig,
and 50 nM for I-TAC. INDO-1–loaded cells were exposed sequentially
to the indicated chemokines, and intracellular [Ca21] changes were mon-
itored as above.2018 I-TAC, a Novel Non–Glu-Leu-Arg (ELR) CXC Chemokine
which would be expected to be present at high concentra-
tions at sites of inflammation.
Recently, several chemokines having specificity for T
cells have been described, including dendritic cell CC
chemokine 1/PARC (pulmonary and activation-regulated
chemokine), TARC (thymus and ARC), and MIP (mac-
rophage inflammatory protein)-3a/LARC (liver and ARC)
(28, 54–56). I-TAC demonstrated significantly greater po-
tency than any of these three chemokines for IL-2–acti-
vated T cells (Gladue, R.P., and T.J. Paradis, unpublished
data). The only chemokine more potent than I-TAC was
SDF-1a, which interacts with CXCR4 (35, 36, Gladue,
R.P., et al., unpublished data). Unlike I-TAC, SDF-1a is
active on naive as well as activated T cells, monocytes, and
granulocytes. It has an important role in development, as
evidenced by the prenatal death that occurs in SDF-1a
knock-out mice, most likely due to a defect in the devel-
opment of the cardiac ventricular septal, as well as defects
in B-cell lymphopoiesis and bone-marrow myelopoiesis
(57). I-TAC differs from SDF-1a in its unique selectivity
for effector T cells and this underscores the importance of
I-TAC in T cell–mediated diseases.
The functional relationship of I-TAC to IP-10 and Hu-
Mig is not clear. Like IP-10, I-TAC is expressed in normal
tissues including thymus, spleen, and pancreas, where it
may be involved in the trafficking of activated/effector T
cells. In addition, IP-10, HuMig, and I-TAC may also play
similar roles in inflammation. IP-10 has been shown to be
expressed in delayed-type hypersensitivity reactions in the
skin, psoriatic plaques, tuberculoid leprosy, and certain tu-
mors (17–19), where it may be important for the recruit-
ment of effector T cells. It is tempting to speculate that I-TAC
might also be expressed in these disease states.
In contrast to the low level of I-TAC expression in nor-
mal tissues, I-TAC is dramatically upregulated by IFN, and
IL-1 synergizes to further increase expression. This, in ad-
dition to I-TAC’s selective activity on T cells, suggests a
role for I-TAC in T cell–mediated inflammatory diseases.
These would most likely be diseases associated with a Th1-
type cytokine profile, where abundant IFN-g and IL-1
would be produced. Examples include autoimmune dis-
eases, delayed-type hypersensitivity responses, certain viral
diseases, and transplant rejection (58). However, the marked
upregulation of I-TAC in astrocytes and microglial cells
upon stimulation by IL-1 and IFN raises the possibility that
I-TAC has a central role in the pathogenesis of neuroin-
flammatory diseases such as meningitis, encephalitis, and
multiple sclerosis.
The role of IL-1 in EAE, an animal model for multiple
sclerosis, has been demonstrated, in that an IL-1 receptor
antagonist has shown beneficial effects (59). Furthermore,
acquisition of a Th1-type cytokine profile is required for
Figure 10. I-TAC binding to
HEK293 cells stably expressing
CXCR3. CXCR3 transfectants
were incubated with radiolabeled
I-TAC and various concentra-
tions of unlabeled chemokines.
Radiolabeled I-TAC bound to
cells was determined as indi-
cated in Materials and Methods.
The top panel shows the dis-
placement of radiolabeled I-TAC
by unlabeled I-TAC, and the
Scatchard analysis used to derive
affinities for the two binding
sites. The lower panels are the
curves showing the displace-
ment of radiolabeled I-TAC by
IP-10 and HuMig. The maximum
amount of I-TAC bound was
5976  6 90 cpm. Parental HEK293
cells bound 1551 6 48 cpm.2019 Cole et al.
EAE disease progression, highlighting the importance of
IL-2 and IFN-g (52, 53). Since IL-2 has been shown to
upregulate CXCR3 (15), and IFN-g synergizes with IL-1
to produce I-TAC, it is tempting to speculate that the fol-
lowing sequence of events might cause pathology in multi-
ple sclerosis. Autoreactive T cells that have entered the
central nervous system initiate the generation of a localized
Th1-type cytokine environment, which leads to the pro-
duction of I-TAC by astrocytes and microglia. This causes
an amplification loop that results in increased infiltration of
autoreactive and bystander effector T cells. Eventually, a
nonspecific inflammatory response is triggered that may cause
lesion formation and demyelination indicative of multiple
sclerosis disease pathology.
In conclusion, we have identified and characterized I-TAC,
a novel non-ELR CXC chemokine highly expressed in
cytokine-stimulated astrocytes. I-TAC has potent chemot-
actic activity on activated T cells and is a higher affinity
ligand for CXCR3 than is IP-10 or HuMig. The unique
regulation of I-TAC by IL-1 and IFN-g, and its high level
production by astrocytes and microglia, suggests an impor-
tant role for this chemokine in central nervous system dis-
eases which involve T cell recruitment.
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